Investigational Drug Information for Rebeccamycin
✉ Email this page to a colleague
What is the development status for investigational drug Rebeccamycin?
Rebeccamycin is an investigational drug.
There have been 12 clinical trials for Rebeccamycin.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2000.
The most common disease conditions in clinical trials are Lung Neoplasms, Neuroblastoma, and Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Case Comprehensive Cancer Center, and Memorial Sloan Kettering Cancer Center.
Summary for Rebeccamycin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,359 |
| WIPO Patent Applications | 833 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 2 (2000-06-01) |
| Vendors | 18 |
Recent Clinical Trials for Rebeccamycin
| Title | Sponsor | Phase |
|---|---|---|
| Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors | National Cancer Institute (NCI) | Phase 1 |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | National Cancer Institute (NCI) | Phase 1 |
| Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Rebeccamycin
Top disease conditions for Rebeccamycin
Top clinical trial sponsors for Rebeccamycin
US Patents for Rebeccamycin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
